Condition (MeSH)
Neglected Diseases
ClinicalTrials.gov lists 41 trials for Neglected Diseases or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
41 of the 41 trials are tagged with Neglected Diseases itself; the rest are tagged with a narrower condition beneath it.
When did Neglected Diseases trials start? (16)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 5 |
| 2024 | 3 |
| 2022 | 6 |
| 2021 | 4 |
| 2019 | 1 |
| 2018 | 2 |
| 2017 | 1 |
| 2016 | 3 |
| 2015 | 1 |
Showing 10 of 16 earlier years.
No forecast is made for this condition: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 34 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 13 months across 22 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Neglected Diseases trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 5 |
| Phase 2/3 | 1 |
| Phase 3 | 4 |
| Phase 4 | 2 |
| Not applicable | 11 |
| Observational | 8 |
How many Neglected Diseases trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 5 |
| Active, not recruiting | 2 |
| Completed | 22 |
| Suspended | 1 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Neglected Diseases trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Arisan Therapeutics, Inc. | 1 |
| Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben | 1 |
Which drugs are being tested for Neglected Diseases? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Ivermectin | 5 |
| Albendazole | 5 |
| Agatolimod Sodium | 2 |
| Emodepside | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| 1% Azithromycin | 2 |
| Na-APR-1 (M74)/Alhydrogel | 2 |
| Na-GST-1/Alhydrogel | 2 |
| Standard [RC8]: rifampicin plus clarithromycin (RC) therapy for 8 weeks. | 1 |
| hepatitis B vaccines | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Neglected Diseases trials report? (3)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Acute kidney injury | 1 | 1 |
| Pneumonia | 1 | 1 |
| Urinary tract infection | 1 | 1 |
Which publications cover Neglected Diseases? (52)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Exploring the impact of mobile and migrant populations on mass drug administration coverage and effectiveness in Africa: A scoping review protocol. | PloS one | 2025 | Yes |
| Fixed-dose ivermectin for Mass Drug Administration: Is it time to leave the dose pole behind? Insights from an Individual Participant Data Meta-Analysis. | PLoS neglected tropical diseases | 2025 | Yes |
| Advanced HIV as a Neglected Disease. | The New England journal of medicine | 2024 | Yes |
| A global call for action to tackle skin-related neglected tropical diseases (skin NTDs) through integration: An ambitious step change. | PLoS neglected tropical diseases | 2023 | Yes |
| Community-based wound management in a rural setting of Côte d'Ivoire. | PLoS neglected tropical diseases | 2022 | Yes |
Showing 5 of 52 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.